These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1324 related items for PubMed ID: 17825691

  • 1. A 12-week, prospective, open-label analysis of the effect of rosuvastatin on triglyceride-rich lipoprotein metabolism in patients with primary dyslipidemia.
    Kostapanos MS, Milionis HJ, Filippatos TD, Nakou ES, Bairaktari ET, Tselepis AD, Elisaf MS.
    Clin Ther; 2007 Jul; 29(7):1403-14. PubMed ID: 17825691
    [Abstract] [Full Text] [Related]

  • 2. Rosuvastatin 5 and 10 mg/d: a pilot study of the effects in hypercholesterolemic adults unable to tolerate other statins and reach LDL cholesterol goals with nonstatin lipid-lowering therapies.
    Glueck CJ, Aregawi D, Agloria M, Khalil Q, Winiarska M, Munjal J, Gogineni S, Wang P.
    Clin Ther; 2006 Jun; 28(6):933-42. PubMed ID: 16860175
    [Abstract] [Full Text] [Related]

  • 3. Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study.
    Strandberg TE, Feely J, Sigurdsson EL, DISCOVERY study group.
    Clin Ther; 2004 Nov; 26(11):1821-33. PubMed ID: 15639694
    [Abstract] [Full Text] [Related]

  • 4. One-year efficacy and safety of rosuvastatin + fenofibric acid combination therapy in patients with mixed dyslipidemia: evaluation of dose response.
    Ferdinand KC, Davidson MH, Kelly MT, Setze CM.
    Am J Cardiovasc Drugs; 2012 Apr 01; 12(2):117-25. PubMed ID: 22263674
    [Abstract] [Full Text] [Related]

  • 5. Baseline triglyceride levels and insulin sensitivity are major determinants of the increase of LDL particle size and buoyancy induced by rosuvastatin treatment in patients with primary hyperlipidemia.
    Kostapanos MS, Milionis HJ, Lagos KG, Rizos CB, Tselepis AD, Elisaf MS.
    Eur J Pharmacol; 2008 Aug 20; 590(1-3):327-32. PubMed ID: 18585701
    [Abstract] [Full Text] [Related]

  • 6. Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial.
    Jones PH, Hunninghake DB, Ferdinand KC, Stein EA, Gold A, Caplan RJ, Blasetto JW, Statin Therapies for Elevated Lipid Levels Compared Across Doses to Rosuvastatin Study Group.
    Clin Ther; 2004 Sep 20; 26(9):1388-99. PubMed ID: 15531001
    [Abstract] [Full Text] [Related]

  • 7. Effect of rosuvastatin compared with other statins on lipid levels and National Cholesterol Education Program goal attainment for low-density lipoprotein cholesterol in a usual care setting.
    Bullano MF, Wertz DA, Yang GW, Kamat S, Borok GM, Gandhi S, McDonough KL, Willey VJ.
    Pharmacotherapy; 2006 Apr 20; 26(4):469-78. PubMed ID: 16553504
    [Abstract] [Full Text] [Related]

  • 8. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
    Harley CR, Gandhi S, Blasetto J, Heien H, Sasane R, Nelson SP.
    Am J Geriatr Pharmacother; 2007 Sep 20; 5(3):185-94. PubMed ID: 17996658
    [Abstract] [Full Text] [Related]

  • 9. Achieving LDL cholesterol, non-HDL cholesterol, and apolipoprotein B target levels in high-risk patients: Measuring Effective Reductions in Cholesterol Using Rosuvastatin therapY (MERCURY) II.
    Ballantyne CM, Bertolami M, Hernandez Garcia HR, Nul D, Stein EA, Theroux P, Weiss R, Cain VA, Raichlen JS.
    Am Heart J; 2006 May 20; 151(5):975.e1-9. PubMed ID: 16644314
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and safety of rosuvastatin and fenofibric acid combination therapy versus simvastatin monotherapy in patients with hypercholesterolemia and hypertriglyceridemia: a randomized, double-blind study.
    Roth EM, McKenney JM, Kelly MT, Setze CM, Carlson DM, Gold A, Stolzenbach JC, Williams LA, Jones PH.
    Am J Cardiovasc Drugs; 2010 May 20; 10(3):175-86. PubMed ID: 20524719
    [Abstract] [Full Text] [Related]

  • 11. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance.
    Sasaki J, Ikeda Y, Kuribayashi T, Kajiwara K, Biro S, Yamamoto K, Ageta M, Kobori S, Saikawa T, Otonari T, Kono S.
    Clin Ther; 2008 Jun 20; 30(6):1089-101. PubMed ID: 18640465
    [Abstract] [Full Text] [Related]

  • 12. Lipid-modifying effects of rosuvastatin in postmenopausal women with hypercholesterolemia who are receiving hormone replacement therapy.
    Shepherd J, Packard C, Littlejohn TW, Walker J, Stein EA, Smith K, Kallend D, Blasetto JW.
    Curr Med Res Opin; 2004 Oct 20; 20(10):1571-8. PubMed ID: 15462690
    [Abstract] [Full Text] [Related]

  • 13. Differential effect of hypolipidemic drugs on lipoprotein-associated phospholipase A2.
    Saougos VG, Tambaki AP, Kalogirou M, Kostapanos M, Gazi IF, Wolfert RL, Elisaf M, Tselepis AD.
    Arterioscler Thromb Vasc Biol; 2007 Oct 20; 27(10):2236-43. PubMed ID: 17656665
    [Abstract] [Full Text] [Related]

  • 14. The DISCOVERY PENTA study: a DIrect Statin COmparison of LDL-C Value--an Evaluation of Rosuvastatin therapY compared with atorvastatin.
    Fonseca FA, Ruiz A, Cardona-Muñoz EG, Silva JM, Fuenmayor N, Marotti M, DISCOVERY PENTA investigators.
    Curr Med Res Opin; 2005 Aug 20; 21(8):1307-15. PubMed ID: 16083541
    [Abstract] [Full Text] [Related]

  • 15. LDL-C/HDL-C ratio in subjects with cardiovascular disease and a low HDL-C: results of the RADAR (Rosuvastatin and Atorvastatin in different Dosages And Reverse cholesterol transport) study.
    Jukema JW, Liem AH, Dunselman PH, van der Sloot JA, Lok DJ, Zwinderman AH.
    Curr Med Res Opin; 2005 Nov 20; 21(11):1865-74. PubMed ID: 16307708
    [Abstract] [Full Text] [Related]

  • 16. Cholesterol-lowering effects of rosuvastatin compared with atorvastatin in patients with type 2 diabetes -- CORALL study.
    Wolffenbuttel BH, Franken AA, Vincent HH, Dutch Corall Study Group.
    J Intern Med; 2005 Jun 20; 257(6):531-9. PubMed ID: 15910557
    [Abstract] [Full Text] [Related]

  • 17. Efficacy and safety of rosuvastatin and atorvastatin in patients with hypercholesterolemia and a high risk of coronary heart disease: a randomized, controlled trial.
    Schwartz GG, Bolognese MA, Tremblay BP, Caplan R, Hutchinson H, Raza A, Cressman M.
    Am Heart J; 2004 Jul 20; 148(1):e4. PubMed ID: 15215813
    [Abstract] [Full Text] [Related]

  • 18. Comparative effects of rosuvastatin and gemfibrozil on glucose, insulin, and lipid metabolism in insulin-resistant, nondiabetic patients with combined dyslipidemia.
    Lamendola C, Abbasi F, Chu JW, Hutchinson H, Cain V, Leary E, McLaughlin T, Stein E, Reaven G.
    Am J Cardiol; 2005 Jan 15; 95(2):189-93. PubMed ID: 15642550
    [Abstract] [Full Text] [Related]

  • 19. Comparative effects of rosuvastatin and atorvastatin on glucose metabolism and adipokine levels in non-diabetic patients with dyslipidaemia: a prospective randomised open-label study.
    Anagnostis P, Selalmatzidou D, Polyzos SA, Panagiotou A, Slavakis A, Panagiotidou A, Athyros VG, Karagiannis A, Mikhailidis DP, Kita M.
    Int J Clin Pract; 2011 Jun 15; 65(6):679-83. PubMed ID: 21564441
    [Abstract] [Full Text] [Related]

  • 20. [Treatment for dyslipidemias in patients with arterial hypertension].
    Chazova IE, Kukharchuk VV, Ratova LG, Kaminnaia VI.
    Ter Arkh; 2007 Jun 15; 79(4):53-7. PubMed ID: 17564020
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 67.